Quince therapeutics provides business update and reports fiscal year 2024 financial results

South san francisco, calif.--(business wire)---- $qncx #biotech--quince therapeutics, inc. (nasdaq: qncx), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the fiscal year ended december 31, 2024. dirk thye, m.d., quince's chief executive officer and chief medical officer, said, “our phase 3 pivotal neat clinical trial has exceeded 50%.
QNCX Ratings Summary
QNCX Quant Ranking